Klotho Neurosciences Inc WT KLTOW

$0.06 0.00 (—)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$1,350,000
P/E (trailing)
—
P/E (forward)
—
Profit margin
—
Debt to equity
—

Trading

Volume
1,513
Avg volume
34,610
Day's range
$0.06 – $0.06
Shares out
—
Stochastic %K
83%
Beta
—
Analysts
—
Price target
—

Price

Company profile

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neur...

Show more

Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Phone
833 931 6330
Website
https://klothoneuro.com
Address
13576 Walnut Street, Suite A, Omaha, United States

Latest news

No headlines yet.